Hyperactivity News and Research

RSS

Simple medical exams recommended for school-age children

Many children and teens are enjoying the remaining days of their summer vacation, but are they truly prepared for what lies ahead? With a few simple medical exams, Virginia's school-age children will be armed with the tools they need to enjoy a healthy school year. The exams we are referring to are given in a doctor's and/or dentist's office, and should take place before or shortly after the start of the new school year, and include a routine doctor's exam to confirm that all immunizations are up-to-date, a dental exam and a vision exam.

27 Aug 2010

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same", U.S. Patent No. 7,776,917 B2. This patent, combined with KemPharm's recently issued U.S. Patent No. 7,772,222, provides broad protection of the Company's Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

27 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

26 Aug 2010

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Cognitive behavioral therapy improves ADHD symptoms in adults: Study

Adults with attention-deficit/hyperactivity disorder (ADHD) who received medication and individual sessions of cognitive behavioral therapy (CBT) showed greater improvement in symptoms through 12 months compared to patients who did not receive CBT, according to a study in the August 25 issue of JAMA.

25 Aug 2010

Study finds multi-modal hemispheric based program improves participant's educational outcomes

A new ADD/ADHD study found that a multi-modal hemispheric based program significantly improved the participant's educational outcomes. The study, "The Effect of Hemispheric Specific Remediation Strategies on the Academic Performance Outcome of Children With ADD/ADHD," was conducted by a research team including, Gerry Leisman, Robert Melillo, Sharon Thum, Mark Ransom, Michael Orlando, Christopher Tice, and Frederick Carrick. The study appears in the current issue of the International Journal of Adolescent Medicine and Health.

24 Aug 2010

Study finds post Katrina period increases mental health issues among children

Key findings documented in American Medical Association's Journal of Disaster Medicine and Public Health Preparedness 60% of children - as many as 20,000 - displaced by Katrina either have serious emotional disorders, behavioral issues and/or are experiencing significant housing instability.One-third of children are reported to have been diagnosed with at least one mental health problem, but fewer than 50% of parents were able to access needed professional services.Children post-Katrina are 4.5 times more likely to have serious emotional disturbance than children not affected by the disaster

23 Aug 2010

NSF issues award to develop techniques for analyzing children's behavior

A team led by the Georgia Institute of Technology has received a $10 million "Expeditions in Computing" award from the National Science Foundation (NSF) to develop novel computing techniques for measuring and analyzing the behavior of children.

20 Aug 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

20 Aug 2010

Dr. Hartung receives Agilent Thought Leader Award for developmental neurotoxicity research

Agilent Technologies Inc. and the Agilent Foundation today announced that Dr. Thomas Hartung has received an Agilent Thought Leader Award in support of his research for the use of toxicity pathways to predict developmental neurotoxicity. This work could help identify possible contributions of chemicals to disorders such as autism and attention hyperactivity disorders.

19 Aug 2010

Prenatal pesticide exposure increases susceptibility to ADHD in children

Exposure to organophosphate (OP) pesticides before birth can increase susceptibility to attention disorders such as attention deficit/hyperactivity disorder (ADHD), according to new research published in the journal Environmental Health Perspectives (EHP). The new study is part of a growing body of research indicating that exposure to OP pesticides can adversely affect brain development.

19 Aug 2010

Teachers' perceptions of poor behavior leads to potential misdiagnosis of ADHD

Nearly 1 million children in the United States are potentially misdiagnosed with attention deficit hyperactivity disorder simply because they are the youngest - and most immature - in their kindergarten class, according to new research by a Michigan State University economist.

18 Aug 2010

Study links child’s date of birth with ADHD diagnosis rate

Rising rates of attention deficit hyperactivity disorder (ADHD) and large differences in diagnosis rates have led to fears that the condition is often being misdiagnosed. A new study from North Carolina State University demonstrates that these concerns are justified. The researchers found large discrepancies in diagnosis and treatment rates based on small differences in children's dates of birth.

18 Aug 2010

BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients

BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria (PKU). BioMarin expects to report results in the first half of 2012.

18 Aug 2010

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222. This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

16 Aug 2010

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Shire plc, the global specialty biopharmaceutical company, announced the divestiture of Daytrana (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which is approved and marketed in the US for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents, will continue to be available for patients through Noven.

11 Aug 2010

FDA clears Curemark's CM – 4612 IND for Phase III clinical trial in ADHD

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that the U.S. Food and Drug Administration has given clearance to Curemark's Investigational New Drug application for a Phase III clinical trial for the use of CM – 4612 in the treatment of attention deficit hyperactivity disorder.

11 Aug 2010

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

Noven Pharmaceuticals, Inc. today announced that it has entered into a Product and Trademark Acquisition Agreement with affiliates of Shire plc pursuant to which Noven will acquire global rights to Daytrana® (methylphenidate transdermal system) from Shire.

11 Aug 2010

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Shire plc, the global specialty biopharmaceutical company, today announced that a Phase 3b study published in Behavioral and Brain Functions found adults with Attention Deficit Hyperactivity Disorder who took once-daily Vyvanse (lisdexamfetamine dimesylate) Capsules CII demonstrated significant improvement in attention.

6 Aug 2010

Parents of kids with autism spectrum disorders more likely to split: Study

A new study has found that couples who have a child with an autism spectrum disorder (ASD) have an 80% risk of getting divorce. The Adolescents and Adults With Autism study involved 391 families with autistic children and compared them with other families whose children were developing normally. The families were matched based on the age, sex and birth order of the child with an ASD, as well as the age, ethnicity and education of the mother.

4 Aug 2010

Hyperactivity News and Research

Simple medical exams recommended for school-age children

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Cognitive behavioral therapy improves ADHD symptoms in adults: Study

Study finds multi-modal hemispheric based program improves participant's educational outcomes

Study finds post Katrina period increases mental health issues among children

NSF issues award to develop techniques for analyzing children's behavior

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Dr. Hartung receives Agilent Thought Leader Award for developmental neurotoxicity research

Prenatal pesticide exposure increases susceptibility to ADHD in children

Teachers' perceptions of poor behavior leads to potential misdiagnosis of ADHD

Study links child’s date of birth with ADHD diagnosis rate

BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

FDA clears Curemark's CM – 4612 IND for Phase III clinical trial in ADHD

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Parents of kids with autism spectrum disorders more likely to split: Study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News